期刊
JOURNAL OF NEUROIMMUNOLOGY
卷 185, 期 1-2, 页码 168-174出版社
ELSEVIER
DOI: 10.1016/j.jneuroim.2007.01.011
关键词
multiple sclerosis; interferon-beta; interleukin-10; interleukin-12; interferon-gamma; biomarker
资金
- NHLBI NIH HHS [T35 HL007612, HL07612-15] Funding Source: Medline
- NINDS NIH HHS [K24 NS002082, K-24-NS02082, K24 NS002082-06] Funding Source: Medline
We investigated serum (IL-10 and IL-12p70) and cellular cytokine levels (IL-10, IL-12p40, IL-12p70, IFN-gamma) in stimulated PBMC over 24 weeks in 15 relapsing-remitting multiple sclerosis (MS) patients randomized to receive once-weekly (qw) IFN-beta-1a 30 mu g intramuscularly (IM) (n=8) or three-times-weekly (tiw) IFN-beta-1a 44 mu g subcutaneously (SC) (n=7). Overall, IFN-beta treatment increased cellular IL-10 (p < 0.01) levels and the ratios of cellular IL-10/IL-12p40 (p < 0.01) and IL-10/IL-12p70 (p < 0.02) while cellular IFN-gamma levels were reduced (p < 0.01). Serum IL-10 levels were decreased in non-responders to therapy based on MRI-defined criteria (p<0.01) but did not change in responders over the course of treatment. In addition, non-responders demonstrated a decrease in serum IL-10/IL-12p70 ratio (p=0.031) and a decrease in cellular IL-12p70 (p < 0.02). A decrease in cellular IFN-gamma was observed in responders (p=0.013). This is the first study that compares cytokine changes between the two IFN-beta regimes and demonstrates that serum IL-10 levels decrease in those patients who continue to have active MRI lesions while on interferon-beta therapy. (c) 2007 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据